Stool Gastrointestinal Panel by PCR (STGIPR)
- 87507 - QTY (1)
- GI PANEL
- STOOL GIP
Cleveland Clinic Laboratories
|Volume||Type||Container||Collect Temperature||Transport Temperature||Special Instructions|
|Ambient||Stability: 4 days|
|Refrigerated||Stability: 4 days|
|Frozen||Frozen specimens are unacceptable and will be rejected|
7 days a week
1 - 2 days
|Qualitative Polymerase Chain Reaction|
The stool must be passed into a clean, dry, wide mouthed container and not contaminated by urine or water. Select bloody, slimy, or watery portions of the stool using the collection spoon provided in the cap of the container. Place enough stool in the Cary-Blair Transport vial (Lawson #125242) to bring the liquid level up to the “fill to here” line. Tighten the cap and shake the vial until the mixture appears homogeneous. Specimens received >96 h after collection, in transport media other than Cary Blair (eg, formalin, PVA, swabs, unpreserved stool), or frozen will be rejected. Stool contaminated with urine or water will be rejected.
Targets detected by this multiplex PCR assay include the following bacteria or associated toxins: Campylobacter spp. [C. jejuni, C. coli, C. upsaliensis], Plesiomonas shigelloides, Salmonella spp., Vibrio spp. [V. parahaemolyticus, V, vulnificus, V. cholerae], Yersinia spp., Enteroaggregative Escherichia coli [EAEC], Enteropathogenic E. coli [EPEC], Enterotoxigenic E. coli [ETEC], and Shiga-like toxin-producing E. coli [STEC] stx1/stx2 with specific identification of E. coli O157 serogroup, Shigella/Enteroinvasive E. coli [EIEC]. Viruses and parasites detected include: Adenovirus F 40/41, Astrovirus, Norovirus GI/GII, Rotavirus A, Sapovirus [Genogroups I, II, IV, V], Cryptosporidium spp., Cyclospora cayetanensis, Entamoeba histolytica, and Giardia intestinalis (formerly G. lamblia). The primary indication for testing is >7 days of moderate to severe diarrheal disease. When clinical symptoms or epidemiologic factors suggest a specific etiology, testing for that agent is recommended before ordering this type of comprehensive panel. For example, testing for Clostridium difficile PCR should be requested for patients with recent exposure to antimicrobial agents. Data supporting the FDA approval is available in J Clin Microbiol, 2015; 53:915-25 http://jcm.asm.org/content/53/3/915.long.
A positive result may indicate viable or nonviable organism. Not all infectious etiologies of diarrhea are detected by the assay. False negatives may occur due to genetic variability in the region targeted by the primers.